Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial

The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.

Inclusion Criteria:

• Older than 18 years
• Diagnosed as hypoactive delirium
• Informed consent given

Exclusion Criteria:

• Pregnancy
• Epilepsy
• M. Parkinson
• Lewy-body dementia
• Prolonged QT-time
• Known allergy to the medicinals used
• Renal replacement therapy
• Hepatic encephalopathy
• Hyperthyroid
• Glaucoma
• Previous suicide attempts
• Syndrome of Gilles de la Tourette
• Patients which cannot receive the medication oral or through a nasogastric tube